Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Apr 29;14(9):1879.
doi: 10.3390/nu14091879.

Oral Supplement Containing Hydroxytyrosol and Punicalagin Improves Dyslipidemia in an Adult Population without Co-Adjuvant Treatment: A Randomized, Double-Blind, Controlled and Crossover Trial

Rebeca Quirós-Fernández  1 , Bricia López-Plaza  1 , Laura M Bermejo  1 , Samara Palma Milla  2 , Andrea Zangara  3   4 , Carmen Gómez Candela  2
Affiliations
Randomized Controlled Trial

Oral Supplement Containing Hydroxytyrosol and Punicalagin Improves Dyslipidemia in an Adult Population without Co-Adjuvant Treatment: A Randomized, Double-Blind, Controlled and Crossover Trial

Rebeca Quirós-Fernández et al. Nutrients. .

Abstract

Hydroxytyrosol (HT) and punicalagin (PC) exert cardioprotective and antiatherosclerotic effects. This study evaluated the effect of an oral supplement containing HT and PC (SAx) on dyslipidemia in an adult population. A randomized, double-blind, controlled, crossover trial was conducted over a 20-week period. SAx significantly reduced the plasma levels of triglycerides (TG) in subjects with hypertriglyceridemia (≥150 mg/dL) (from 200.67 ± 51.38 to 155.33 ± 42.44 mg/dL; p < 0.05), while no such effects were observed in these subjects after the placebo. SAx also significantly decreased the plasma levels of low-density lipoprotein cholesterol (LDL-C) in subjects with high plasma levels of LDL-C (≥160 mg/dL) (from 179.13 ± 16.18 to 162.93 ± 27.05 mg/dL; p < 0.01), while no such positive effect was observed with the placebo. In addition, the placebo significantly reduced the plasma levels of high-density lipoprotein cholesterol (HDL-C) in the total population (from 64.49 ± 12.65 to 62.55 ± 11.57 mg/dL; p < 0.05), while SAx significantly increased the plasma levels of HDL-C in subjects with low plasma levels of HDL-C (<50 mg/dL) (from 44.25 ± 3.99 to 48.00 ± 7.27 mg/dL; p < 0.05). In conclusion, the supplement containing HT and PC exerted antiatherosclerotic and cardio-protective effects by considerably improving dyslipidemia in an adult population, without co-adjuvant treatment or adverse effects.

Keywords: atherosclerosis; cardiovascular disease; dyslipidemia; high-density lipoprotein cholesterol; hydroxytyrosol; low-density lipoprotein cholesterol; punicalagin; total cholesterol; triglycerides.

PubMed Disclaimer

Conflict of interest statement

A.Z. is employed by Euromed S.A. but had no role in the design, collection and/or analysis of the data.

Figures

Figure 1
Figure 1
Flow chart depicting the present study.
Figure 2
Figure 2
The plasma levels of low-density lipoprotein cholesterol (LDL-C) significantly decreased after SAx treatment (oral supplementation with hydroxytyrosol (HT) and punicalagin (PC)) (black color) in subjects with high plasma levels of LDL-C, a risk factor for CVD, (n = 16) (** p < 0.01). This effect was not observed after placebo treatment (gray color). The data represent the adjusted means ± standard deviations (SDs) from multivariate models.
Figure 3
Figure 3
Plasma levels of high-density lipoprotein cholesterol (HDL-C) significantly increased after SAx treatment (oral supplementation with hydroxytyrosol (HT) and punicalagin (PC)) (black color) in subjects with low plasma levels of HDL-C, a risk factor for CVD, (n = 8) (* p < 0.05). This effect was not observed after placebo treatment (gray color). The data represent the adjusted means ± standard deviations (SDs) from multivariate models.
Figure 4
Figure 4
Plasma levels of triglycerides (TG) significantly decreased following SAx treatment (oral supplementation with hydroxytyrosol (HT) and punicalagin (PC)) (black color) in subjects with hypertriglyceridemia, a risk factor for CVD, (n = 4) (* p < 0.05). This effect was not observed after placebo treatment (gray color). The data repreScheme.
See this image and copyright information in PMC

References

    1. WHO Cardiovascular Diseases (CVDs) [(accessed on 19 February 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...
    1. Kaptoge S., Pennells L., De Bacquer D., Cooney M.T., Kavousi M., Stevens G., Riley L.M., Savin S., Khan T., Altay S., et al. World Health Organization cardiovascular disease risk charts: Revised models to estimate risk in 21 global regions. Lancet Glob. Health. 2019;7:e1332–e1345. doi: 10.1016/S2214-109X(19)30318-3. - DOI - PMC - PubMed
    1. WHO Cardiovascular Diseases (CVDs) [(accessed on 7 September 2016)]. Available online: http://www.who.int/mediacentre/factsheets/fs317/en/
    1. WHO . Global Atlas on Cardiovascular Disease Prevention and Control. The World Health Organization Press in Collaboration with the World Heart Federation and the World Stroke Organization; Geneva, Switzerland: 2011.
    1. Roth G.A., Johnson C., Abajobir A., Abd-Allah F., Abera S.F., Abyu G., Ahmed M., Aksut B., Alam T., Alam K., et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. 2017;70:1–25. doi: 10.1016/j.jacc.2017.04.052. - DOI - PMC - PubMed

Publication types

LinkOut - more resources